Jacques Normand, Ph'D'

1
NIDAs New HIV/AIDS Research Program

• Jacques Normand, Ph.D.
• Director, AIDS Research Program
• National Institute on Drug Abuse

2
Objectives

• Update on NIDAs New AIDS Research Program
• CAMCODA
• NIDA Council Recommendations
• New AIDS Research Program
• Structure
• Research Priorities
• Brief Update on NIDA/NIH Collaborative Projects
• Projects and Partners
• New HPTN Network Drug Abuse Projects

3
CAMCODA Structure
Director
Deputy Director
Population-Based Intervention Unit
Human Development Unit
Medical Consequence Unit
Staff 20 Professionals
4
NIDA AIDS FY03 AIDS Funding by Divisions
5
NIDA Advisory Council Workgroup on HIV/AIDS
Report on Findings and Recommendations February,
2004
6
Structural Procedural Recommendations

• Create new position of Director, AIDS Research
  Program reporting to NIDAs Director
• Update policy/procedures to determine which
  projects qualify for AIDS funding
• Improve articulation of HIV/AIDS mission and
  planning process within across
  Divisions/Centers
• Increase interaction across NIH, and with
  extramural community

7
NIDAs AIDS Research Program Structure
AIDS Research Program Mission Plan, develop,
coordinate and integrate research priorities
within NIDA and externally. Staff Jacques
Normand Lynda Erinoff Helen Cesari
AIDS Workgroup AIDS Coding Subgroup
External Scientific AIDS Workgroup TBA
8
NIDAs AIDS Workgroup Membership
Division of Pharmacotherapies and Medical
Consequences of Drug Abuse Jag Khalsa Ahmed
Elkashef Jamie Biswas Division of Basic
Neurosciences and Behavioral Research Diane
Lawrence Cora Lee Wetherington Charles
Sharp Yu Lin Minda Lynch
9
NIDAs AIDS Workgroup Membership (Cont.)
Division of Epidemiology, Services, and
Prevention Research Elizabeth Lambert Division
of Clinical Neurosciences, Development and
Behavioral Treatment Lisa Onken Melissa
Racioppo Nicolette Borek Ro Nemeth Center for
Clinical Trials Network Mary Ellen Michel
10
NIDAs AIDS Workgroup Membership (Cont.)
Office of Science Policy Communication Anna
Staton International Program Steve
Gust Intramural Research Program John
Schmittner Office of Extramural Affairs Mark
Green Office of Planning Research
Management Stacy Gardner
11
External Scientific AIDS Workgroup
Proposed Membership ( 8) Council
Members Nominee per Division/Center Nominee
from AIDS Program Proposed Task Review NIDAs
AIDS Strategic Plan Review make
recommendations on new AIDS related
procedural change (e.g., definition of AIDS and
coding guidelines)
Review NIDAs priorities/initiatives
12
FY04 AIDS Funding by NIDA Divisions
13
NIDAs FY04 Funding By OAR Research Areas of
Emphasis

• Natural History and Epidemiology
  54,246,859
• Etiology and Pathogenesis 29,028,598
• Therapeutics 12,084,141
• Vaccines 1,983,201
• Behavioral and Social Science
  186,583,465
• Training, Infrastructure, and
• Capacity Building 6,860,742
• 7. Information Dissemination
  1,594,994

14
Research Priority Recommendations
Update programs with continuous review of
epidemiologic and other findings

• Racial/ethnic disparities
• Emphasize case finding/treatment
• HAART interactions/adherence/resistance
• Newer HIV/IDU epidemics (Russia, China, India,
  Eastern Europe)
• Test drug Tx for HIV prevention
• Emerging drugs (e.g., Meth/Viagra, NYC
  case/immunological CNS impact )
• Sexual risk behaviors (main exposure category)
• Adolescents (developmental/decision making,
  impulsivity)
• Role of drug abuse on transmission (drug type,
  partnership, context)

15
Current NIDAs AIDS Program Tasks

• Explore new ways to attract new AIDS PIs
• Better integrate HIV/AIDS within and across
• NIDA Divisions/Centers and other NIH
  Institutes
• Working on Generating FY07 OAR Priorities
• (retooling priorities to establish strong
  presence in all Div/Ctr)
• Will be Generating NIDA FY06 AIDS Initiatives
• Developing Criteria for AIDS Grants
• Will be Appointing Members to Extramural
• Scientific AIDS Workgroup
• Will be Developing NIDAs HIV/AIDS Strategic Plan

16
NIDAs CollaborativeProjects
17
HPTN New NIAID Network

• Current Projects
• Epidemiology
• HIV Prevention
• Drug Tx as HIV Prevention
• New Network
• Proposed protocols
• Community Scale-up
• Stimulant pharmacotherapy as HIV prevention